Better HIV market outlook: AIDS 2026 conference to show pipeline progress

Research evidence excerpt

Better HIV market outlook: AIDS 2026 conference to show pipeline progress

24 July 2026

Equities

Healthcare Better HIV market outlook

AIDS 2026 conference to show pipeline progress Global

◆ Consensus expects HIV growth to slow as Biktarvy matures Morten Herholdt*

and dolutegravir goes generic, we see a better outlook Global Life Sciences & Healthcare Analyst

HSBC Bank plc

morten.herholdt@hsbc.com

◆ The AIDS 2026 conference in Rio, starting this Sunday, should + 44 20 7992 4082

provide insight into new growth drivers Rajesh Kumar*

Senior Global Life Sciences & Healthcare Analyst

◆ We run our forensic lens over the most important trials, rajesh4kumar@hsbcib.com

highlighting a robust outlook for product launches +44 20 7991 1629

Shubhangi Gupta*, PhD

Global Life Sciences & Healthcare Analyst

Not a fading market segment: Many investors fear a slowing HIV market as Biktarvy HSBC Securities and Capital Markets (India) Private Limited

matures and dolutegravir begins losing patent protection. We see continued growth for shubhangi.gupta@hsbc.co.in

+91 80 4555 2143

the rest of the decade and into the next. Relative to other markets, HIV has protective

regulation, favourable access and room to address both resistance and higher Yessica Sanchez* Global Life Sciences & Healthcare Analyst

sensitivity to adherence – all enjoyed by a very small group of just three companies. HSBC Mexico, S.A., Institucion de Banca Multiple, Grupo

Financiero HSBC

There is currently an elevated level of innovation as new mechanisms (Capsid inhibitor yessica.sanchez@hsbc.com.mx

Lenacapavir) are being approved, and new oral combinations are coming, offering +55 52 8551 7904

longer dosing intervals for both injectable and oral options. Longer acting options have Damayanti Kerai*